CME: Myeloma bone disease: Monitoring and management
ACCREDITATION EXPIRED: December 21, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.
Target Audience:
The following healthcare professionals: hematologists who treat patients with MM and medical oncologists; physician assistants, nurse practitioners, and pharmacists who treat patients with MM; and any other HCPs with an interest in or who commonly care for patients with MM.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen.
This activity is free of charge.
Release Date: December 21, 2022 -- Expiration Date: December 21, 2024
Faculty: C. Ola Landgren, MD, PhD
Agenda
|
Faculty introduction, disclosures |
|
Overview of MM-related Bone Disease
|
|
Bone-Targeted Supportive Care
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Review the pathophysiology of MM-related bone disease and subsequent SREs, emphasizing relevant treatment targets
- Describe the impact of MM-related bone disease and SREs on quality of life, morbidity, and mortality
- Compare the safety and efficacy of bone-modifying agents for the management of MM-related bone disease, and apply them to patient cases based on guideline recommendations
- Discuss evidence-based strategies for monitoring bone health in patients with both smoldering myeloma and active MM
Accreditation
ACCME Activity #202369985
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: C. Ola Landgren, MD, PhD, Chief, Myeloma Division, University of Miami Miller School of Medicine, has received financial compensation from: TGSK, Sanofi, Astra-Zeneca, Adaptive Biotech, Celgene, Janssen,Takeda, Merck, Amgen, BMS, Karyopharm, and Pfizer for consulting work.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Sickle cell disease (SCD): A focus on updates in therapy
Pyruvate kinase deficiency (PKD): zeroing in on gaps in identification and treatment
Gaps in the identification and treatment of hemophilia B: what are the missing factors?